Report cover image

Parkinson's Disease Therapeutics Market, Opportunity, Growth Drivers, Industry Trend Analysis and Forecast, 2025-2034

Publisher Global Market Insights
Published May 13, 2025
Length 130 Pages
SKU # GMI20156873

Description

The Global Parkinson’s Disease Therapeutics Market was valued at USD 5.5 billion in 2024 and is estimated to grow at a CAGR of 8.1% to reach USD 11.9 billion by 2034, driven by the rising global prevalence of Parkinson’s disease due to an aging population, advancements in drug delivery technologies, and growing R&D investments by biopharmaceutical companies. The aging population is a key driver of demand, as Parkinson’s disease predominantly affects individuals over 60. With better diagnostic capabilities and increased awareness, early-stage diagnoses are becoming more frequent, opening up avenues for early intervention and disease-modifying treatments.

Parkinson’s disease therapeutics encompass a range of pharmacological treatments that aim to restore dopamine activity in the brain or manage both motor and non-motor symptoms. The market is experiencing a shift toward extended-release formulations and novel non-dopaminergic agents targeting neuroprotective pathways. Increasing patient advocacy, improved reimbursement in developed regions, and innovative product pipelines are also contributing to market expansion.

The Parkinson’s Disease Therapeutics Market is primarily segmented by drug class, with levodopa/carbidopa leading the market in 2024, generating USD 2.6 billion. This drug combination remains the gold standard for managing motor symptoms due to its proven efficacy and widespread use across all stages of Parkinson’s. Its affordability, including the availability of generic versions, reinforces its dominant market position.

In terms of disease type, early-stage Parkinson’s disease dominated the market in 2024, contributing USD 2.7 billion, driven by improved screening tools and physician awareness. The shift towards early diagnosis has significantly increased demand for therapies that delay disease progression and enhance quality of life during the initial stages of the condition.

Based on the route of administration, the oral segment accounted for the largest revenue share at USD 3.5 billion in 2024. Oral therapies are favored for their convenience, ease of use, and compatibility with chronic treatment regimens in older populations. Ongoing developments in extended-release and targeted oral formulations further drive growth in this segment.

By patient type, adults represented the dominant share of the market in 2024, generating USD 5.3 billion, fueled by the global increase in life expectancy and age-related susceptibility to Parkinson’s disease. Treatment adherence among elderly populations is also improving due to simplified dosing regimens and advancements in drug formulations.

The U.S. Parkinson’s Disease Therapeutics Market led globally, with a market value of USD 2.3 billion in 2024, and is projected to reach USD 4.7 billion by 2034 at a CAGR of 7.6%. The U.S. benefits from a robust reimbursement infrastructure, a large aging population, and substantial federal research funding. Medicare and private insurers increasingly cover advanced treatments such as deep brain stimulation and extended-release formulations, enhancing patient access and adherence.

Key companies operating in the Parkinson’s Disease Therapeutics Market include Acadia Pharmaceuticals, AbbVie, Acorda Therapeutics (Merz Therapeutics), Boehringer Ingelheim, Amneal Pharmaceuticals, Desitin Arzneimittel, Kyowa Kirin, Newron Pharmaceuticals, F. Hoffmann-La Roche, Novartis, Sumitomo Dainippon Pharma, Orion Pharma, Supernus Pharmaceuticals, Teva Pharmaceutical, and UCB S.A. These firms are actively investing in R&D, strategic collaborations, and product innovation to enhance their market positions. Many are focusing on the development of novel delivery systems, disease-modifying therapies, and expanding access to underserved regions.

As the burden of Parkinson’s disease continues to grow globally, the therapeutic landscape is expected to become increasingly dynamic, characterized by scientific innovation, regulatory support, and expanding treatment accessibility.

Table of Contents

130 Pages
Chapter 1 Methodology
1.1 Industry coverage
1.2 Market scope and definitions
1.3 Research design
1.4 Market size estimates and calculations
1.4.1 Approach 1: Company revenue share analysis
1.4.2 Approach 2: Data mining approach (investor presentations)
1.4.3 Approach 3: Parent market analysis
1.5 Key trends for market estimates
1.6 Forecast model
1.7 Primary research & validation
1.7.1 Primary sources
1.7.2 Data mining sources
1.7.2.1 Paid sources 21
1.7.2.2 Public sources
Chapter 2 Executive Summary
2.1 Industry 360 degree synopsis
2.1.1 Business trends
2.1.2 Regional trends
2.1.3 Drug class trends
2.1.4 Disease type trends
2.1.5 Route of administration trends
2.1.6 Patient trends
Chapter 3 Industry Insights
3.1 Industry ecosystem
3.2 Industry impact forces
3.2.1 Growth drivers
3.2.1.1 Rising global prevalence of Parkinson's disease due to an aging population
3.2.1.2 Advancements in drug delivery technologies and novel formulations
3.2.1.3 Growing research and development investments by biopharmaceutical companies 37
3.2.1.4 Strong support from non-profits and advocacy organizations
3.2.2 Industry pitfall
3.2.2.1 High cost of advanced therapies and limited reimbursement in low- income regions
3.3 Growth potential analysis
3.3.1 By drug class
3.3.2 By disease type
3.3.3 By route of administration
3.3.4 By patient
3.4 Regulatory landscape
3.5 Epidemiology landscape
3.6 Pipeline analysis
3.7 Future market trends
3.8 Porter's analysis
3.9 PESTEL analysis
Chapter 4 Competitive Landscape, 2024
4.1 Introduction
4.1.1 AbbVie
4.1.2 Novartis
4.1.3 F. Hoffmann-La Roche
4.2 Company matrix analysis
4.3 Competitive analysis of major market players
4.4 Competitive positioning matrix
4.5 Strategy dashboard
Chapter 5 Parkinson's Disease Therapeutics Market, By Drug Class
5.1 Levodopa/carbidopa
5.2 Dopamine agonist
5.3 Adenosine A2A antagonist
5.4 COMT Inhibitors
5.5 MAO-B inhibitors
5.6 Glutamate antagonist
5.7 Cholinesterase inhibitors
5.8 Other drug classes
Chapter 6 Parkinson's Disease Therapeutics Market, Disease Type
6.1 Early-stage PD
6.2 Moderate-stage PD
6.3 Advanced-stage PD
6.4 PD with dementia (PDD)
Chapter 7 Parkinson's Disease Therapeutics Market, Route of Administration
7.1 Oral 71
7.2 Subcutaneous
7.3 Transdermal
7.4 Other routes of administration
Chapter 8 Parkinson's Disease Therapeutics Market, By Patient
8.1 Adult 74
8.2 Pediatric
Chapter 9 Parkinson's Disease Therapeutics Market, By Region
9.1 U.S. 76
9.2 Europe
9.3 Asia Pacific
Chapter 10 Company Profiles
10.1 AbbVie
10.1.1 Financial data
10.1.1.1 Sales revenue, 2021-2024 (USD Million)
10.1.2 Product landscape
10.1.3 Strategic outlook
10.1.4 SWOT analysis
10.2 Acadia Pharmaceuticals
10.2.1 Financial data
10.2.1.1 Sales revenue, 2021-2024 (USD Million)
10.2.2 Product landscape
10.2.3 SWOT analysis
10.3 Acorda Therapeutics (Merz Therapeutics)
10.3.1 Financial data
10.3.2 Product landscape
10.3.3 Strategic outlook
10.3.4 SWOT analysis
10.4 Amneal Pharmaceuticals
10.4.1 Financial data
10.4.1.1 Sales revenue, 2021-2024 (USD Million)
10.4.2 Product landscape
10.4.3 Strategic outlook
10.4.4 SWOT analysis
10.5 Boehringer Ingelheim
10.5.1 Financial data
10.5.1.1 Sales revenue, 2021-2024 (USD Million)
10.5.2 Product landscape
10.5.3 SWOT analysis
10.6 Desitin Arzneimittel
10.6.1 Financial data
10.6.2 Product landscape
10.6.3 SWOT analysis
10.7 F. Hoffmann-La Roche
10.7.1 Financial data
10.7.1.1 Sales revenue, 2021-2024 (USD Million)
10.7.2 Product landscape
10.7.3 Strategic outlook
10.7.4 SWOT analysis
10.8 Kyowa Kirin
10.8.1 Financial data
10.8.1.1 Sales revenue, 2021-2024 (USD Million)
10.8.2 Product landscape
10.8.3 SWOT analysis
10.9 Newron Pharmaceuticals
10.9.1 Financial data
10.9.1.1 Sales revenue, 2021-2024 (USD Million)
10.9.2 Product landscape
10.9.3 SWOT analysis
10.10 Novartis
10.10.1 Financial data
10.10.1.1 Sales revenue, 2021-2024 (USD Million)
10.10.2 Product landscape
10.10.3 SWOT analysis
10.11 Orion Pharma
10.11.1 Financial data
10.11.1.1 Sales revenue, 2021-2024 (USD Million)
10.11.2 Product landscape
10.11.3 Strategic outlook
10.11.4 SWOT analysis
10.12 Sumitomo Dainippon Pharma
10.12.1 Financial data
10.12.1.1 Sales revenue, 2020-2023 (USD Million)
10.12.2 Product landscape
10.12.3 SWOT analysis
10.13 Supernus Pharmaceuticals
10.13.1 Financial data
10.13.1.1 Sales revenue, 2021-2024 (USD Million)
10.13.2 Product landscape
10.13.3 Strategic outlook
10.13.4 SWOT analysis
10.14 Teva Pharmaceutical
10.14.1 Financial data
10.14.1.1 Sales revenue, 2021-2024 (USD Million)
10.14.2 Product landscape
10.14.3 SWOT analysis
10.15 UCB S.A.
10.15.1 Financial data
10.15.1.1 Sales revenue, 2021-2024 (USD Million)
10.15.2 Product landscape
10.15.3 SWOT analysis

Search Inside Report

Pricing

Currency Rates
How Do Licenses Work?

How Do Licenses Work?

The primary function of a report license is to define how many people within a company are authorized to use the purchased report. This is separate to how a report might be delivered. Unless specifically identified otherwise, the purchase option is Single User. Below is a helpful description of that license, along with a sampling of others most commonly offered.

  • This license allows only one user to have access to and to use/read the report. It is not one user at a time or one user group; it is an individual who will be reading and utilizing the report.

  • This license allows for the entire purchasing company to read and use the report. This is the license level that would allow for a report to be placed on an internal company shared drive for access by all employees of that direct company. This license does not extend to parent or sister company use.

  • This license is designed to allow an entire department within a company full access to a report. The departmental license is a great option for companies that have more than one location and the department is spread out all over the country/world

  • This license is for companies that have one location where they want the report to be accessible by all employees within that physical location.

  • This is the most flexible of the licensing options. Some publishers will allow you to get a license for a preset number of people (typically 5). These licenses are ideal for small work groups.

License options are at the discretion of each publisher. As such, not all licenses indicated above are available for every product. If you are uncertain of the best license for your needs or would like a license that is not proactively available, please contact us and we will be happy to assist.

Head shot

Questions or Comments?

Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
Chat Now
Contact Us